Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. - Wikidata - wikimedia - TriplyDB

Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.

Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.

http://www.wikidata.org/entity/Q34482254

about

Enzyme replacement and substrate reduction therapy for Gaucher disease Imiglucerase in the treatment of Gaucher disease: a history and perspective Gaucher disease: the role of the specialist on metabolic bone diseases Understanding the natural history of Gaucher disease Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments Revised recommendations for the management of Gaucher disease in children.The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients.Hematological manifestations and complications of Gaucher disease.Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat.Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)Disease-drug pairs revealed by computational genomic connectivity mapping on GBA1 deficient, Gaucher disease mice.Bone turnover markers in patients with type 1 Gaucher disease.Early diagnosis of Gaucher disease in pediatric patients: proposal for a diagnostic algorithm.Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.Management of bone disease in Gaucher disease type 1: clinical practice.Pathogenesis of Bone Alterations in Gaucher Disease: The Role of Immune System.Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry.Long-term treatment outcomes in Gaucher disease.Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation.Early manifestations of type 1 Gaucher disease in presymptomatic children diagnosed after parental carrier screening.A disease severity scoring system for children with type 1 Gaucher disease.Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.Evaluation of bone involvement in patients with Gaucher disease: a semi-quantitative magnetic resonance imaging method (using ROI estimation of bone lesion) as an alternative method to semi-quantitative methods used so far.The history and accomplishments of the ICGG Gaucher registry.Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS).Tandem mass spectrometry assay of β-glucocerebrosidase activity in dried blood spots eliminates false positives detected in fluorescence assay.Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.Oral health of a child being treated for subtype I Gaucher's disease.

P2860

Q24187121-7B5EF5CD-80B2-4BF8-9F70-F3D6CC9ACF31 Q24631426-3F5F3EE8-E1F3-493A-956C-02DB229FDEB3 Q26775745-BD13535A-A371-4A5F-A13B-72F544DEAF27 Q26865974-470022B7-B50C-4DF3-9FCF-65CABA85F33D Q28067032-6D3B26B2-37D5-43D9-8AC8-7D71622A9D40 Q30235844-0824BC55-7BE6-402E-AC24-4746C0A1A2EB Q33402191-6F557E73-B228-467E-BA67-11AB3D924799 Q33403714-58440A84-0E5A-44E9-98A4-4DA729B90EC4 Q33427535-1AB0122F-5AF6-4138-80A2-68E65AC0F5DC Q33634529-FC4D7C23-7305-4A0D-A95E-3DD66510A08E Q34079226-0E0D7F3F-9D8A-4AFA-B29E-6A35CDAE7DD0 Q34311272-7D680570-07A8-41F7-8B33-732E54238640 Q35754621-50DB372A-114E-4752-989B-3EE9BD6B771A Q36040753-0925CB16-9CA3-4B60-BEFE-B51B159993C1 Q36562916-E7498991-7F88-4709-B935-E2D7EDF51A41 Q38240658-4FEB7280-F449-4CA3-86A1-F5453A0146F9 Q38262722-E431F224-3E1B-4B4D-8F0B-4BA76A20B6C9 Q38290826-3E774A3F-B928-49AD-A2F0-34F290B8DF1D Q38524847-6AC207A4-ADF5-4F70-A03E-1CF52EA98D33 Q38533848-065B9176-CF0B-4C76-B71F-A2BF313B048E Q38533851-145532C9-4BBE-4486-B4FB-6AB1C5B870F6 Q38927495-707B8A31-C315-4DE8-8276-81460B786A0E Q38979512-D54625CE-4FEB-49CD-A3EC-910F3931531A Q39550380-6854059C-41D3-4148-BB36-DAB28BB7F5F5 Q40649689-25FEEB67-D49A-48AD-A3BA-3719A824374E Q41489523-C26DDAF3-BC47-4F8F-A1C0-334F8349A58F Q41652308-43172484-3211-4A2D-B249-A28918D33082 Q41901693-8121BB27-05D1-4B1C-A51A-327067E14BA1 Q48091055-0B3355EE-6B2B-4F88-BF8B-88EE55B7C817 Q50178933-7F7BD631-747D-4CF0-B62A-72CA6FFF4193 Q50281421-6591BF4D-C4A0-4E26-9AA2-06224816F608 Q53128627-48CA0C49-E4FD-41B2-8B95-A76B635AF0E7 Q54293297-2EF95EC5-EAAC-4301-87C8-587750AD25AD

P2860

Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.

http://www.wikidata.org/entity/Q34482254

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Osteopenia in Gaucher disease ...... ldren, adolescents and adults.

@ast

Osteopenia in Gaucher disease ...... ldren, adolescents and adults.

@en

Osteopenia in Gaucher disease ...... ldren, adolescents and adults.

@nl

type

label

Osteopenia in Gaucher disease ...... ldren, adolescents and adults.

@ast

Osteopenia in Gaucher disease ...... ldren, adolescents and adults.

@en

Osteopenia in Gaucher disease ...... ldren, adolescents and adults.

@nl

prefLabel

Osteopenia in Gaucher disease ...... ldren, adolescents and adults.

@ast

Osteopenia in Gaucher disease ...... ldren, adolescents and adults.

@en

Osteopenia in Gaucher disease ...... ldren, adolescents and adults.

@nl

P1433

Q34482254-64ACEB10-FA31-4402-9A15-CBF5AF3E255A

P1476

Q34482254-6AE8297C-69BF-4C3E-B35B-32522C9CCA57

P2093

Q34482254-17B6D4C3-4D56-4961-9F7D-AF91366E3C2D

Q34482254-868219A8-8DD7-4DFC-94E3-A73441637506

Q34482254-A637900B-2781-4B84-A9A8-8D45CE16E89F

Q34482254-BE7269FC-435A-44A2-A17D-898646BAFB32

Q34482254-F75C046F-BF52-4B68-AF85-D33929437D72

Q34482254-FBC66804-54A2-414B-9CB9-EA705B9C8B31

P2860

Q34482254-06A0A9FB-37BC-4928-9FE5-326BA4B41F21

Q34482254-0935B027-ED63-4F5E-A627-01B1DD71E614

Q34482254-1652ED4D-C8B1-4C4A-B747-F17E92AAFE4F

Q34482254-20027467-6CEF-49BE-A8A7-145958C37113

Q34482254-35D37ABB-97CA-49EE-A8F3-0EDEFFC0DFDE

Q34482254-52D7F659-D9DF-4235-AD35-D97E4FE9D21B

Q34482254-52D93DD9-EB9D-424D-A5CB-A311D1D187F7

Q34482254-72244FE4-2FB4-4EA9-9492-96B12361010F

Q34482254-7777DDF3-E282-4577-B725-3E4B1C757661

Q34482254-8472E2CD-8CF8-44DD-95D6-D88F0CBBB6C8

P304

Q34482254-1A3D7610-0D70-471B-A46B-600B1C6474E7

P31

Q34482254-9DC54A10-A070-47B0-83EA-9348A75885DA

P356

Q34482254-44B02E9A-3A8E-4335-B97F-40FF193B8C5C

P433

Q34482254-20AA16B6-F599-42C6-A3A5-122971A49118

P478

Q34482254-B5581747-08F1-48E5-BD96-BE5A30E59011

P577

Q34482254-C98519B2-885C-491B-B649-C6797E6D6562

P5875

Q34482254-7DDED600-ED87-4F3B-B0AF-719FB4E23E2C

P698

Q34482254-1FB464B0-85C5-4C84-AF6B-6C584D1075BA

P921

Q34482254-B40951EE-A486-405E-BE64-8903ABF9CFEE

P932

Q34482254-82A36478-4F08-4D3C-98CF-BEBE4094DBC0

P356

J.BCMD.2010.10.011

P1433

Blood Cells, Molecules and Diseases

P1476

Osteopenia in Gaucher disease ...... ldren, adolescents and adults.

@en

P2093

Andrea R Gwosdow

http://www.w3.org/2001/XMLSchema#string

J Alexander Cole

http://www.w3.org/2001/XMLSchema#string

Neal J Weinreb

http://www.w3.org/2001/XMLSchema#string

Paige Kaplan

http://www.w3.org/2001/XMLSchema#string

Pramod K Mistry

http://www.w3.org/2001/XMLSchema#string

Thomas Hangartner

http://www.w3.org/2001/XMLSchema#string

P2860

Life expectancy in Gaucher disease type 1

Imiglucerase and its use for the treatment of Gaucher's disease

CDC growth charts: United States

Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy.

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.

Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence.

Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model.

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage.

Fitting of bone mineral density with consideration of anthropometric parameters

P304

66-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BCMD.2010.10.011

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49640642

http://www.w3.org/2001/XMLSchema#string

P698

21112800

http://www.w3.org/2001/XMLSchema#string

P921

P932

3019260

http://www.w3.org/2001/XMLSchema#string